A 2/1 Sunitinib Dosing Schedule Provides Superior Effectiveness and Less Toxicity Than a 4/2 Schedule for mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Front Oncol 2020 Mar 01;[EPub Ahead of Print], H Deng, M Li, Q Wu, L Wang, Z Hong, F Yi, Y Wei, W ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.